Clinical Trial Detail

NCT ID NCT04464226
Title Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Recruitment Not yet recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Bayer
Indications

cancer

Therapies

Darolutamide

Age Groups: senior adult

No variant requirements are available.